RxDoctor Payments Data

Alex Watson

Family · Mooresville, NCNPI 1710576442

Payments from drug & device makers

$5,629in general payments, 2019–2025

Across 322 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$805
  • AbbVie$713
  • Novo Nordisk$616
  • Pfizer$459
  • AstraZeneca$381
  • Boehringer Ingelheim$362
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,629100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,629 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$21,729
Medicare patients
82
Services billed
565

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin17$22,287
OzempicSemaglutide11$12,776
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,835
VascepaIcosapent Ethyl13$6,999
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,285
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$508
Atorvastatin Calcium76$500
Pramipexole DihydrochloridePramipexole Di-Hcl12$436
Omeprazole29$396
Prednisone32$381
Albuterol Sulfate HfaAlbuterol Sulfate16$380
Metoprolol Succinate35$339
Fenofibrate12$297
Fluticasone Propionate18$265
Montelukast Sodium28$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$362$22,28717 claims
Novo NordiskOzempic$616$12,77611 claims
AstraZenecaBreztri Aerosphere$381$11,83517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →